TY - JOUR
T1 - ACTIVating Resources for the COVID-19 Pandemic
T2 - In Vivo Models for Vaccines and Therapeutics
AU - Hewitt, Judith A.
AU - Lutz, Cathleen
AU - Florence, William C.
AU - Pitt, M. Louise M.
AU - Rao, Srinivas
AU - Rappaport, Jay
AU - Haigwood, Nancy L.
N1 - Publisher Copyright:
© 2020
PY - 2020/11/11
Y1 - 2020/11/11
N2 - The Preclinical Working Group of Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV), a public-private partnership spearheaded by the National Institutes of Health, has been charged with identifying, prioritizing, and communicating SARS-CoV-2 preclinical resources. Reviewing SARS-CoV-2 animal model data facilitates standardization and harmonization and informs knowledge gaps and prioritization of limited resources. To date, mouse, hamster, ferret, guinea pig, and non-human primates have been investigated. Several species are permissive for SARS-CoV-2 replication, often exhibiting mild disease with resolution, reflecting most human COVID-19 cases. More severe disease develops in a few models, some associated with advanced age, a risk factor for human disease. This review provides a snapshot that recommends the suitability of models for testing vaccines and therapeutics, which may evolve as our understanding of COVID-19 disease biology improves. COVID-19 is a complex disease, and individual models recapitulate certain aspects of disease; therefore, the coordination and assessment of animal models is imperative.
AB - The Preclinical Working Group of Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV), a public-private partnership spearheaded by the National Institutes of Health, has been charged with identifying, prioritizing, and communicating SARS-CoV-2 preclinical resources. Reviewing SARS-CoV-2 animal model data facilitates standardization and harmonization and informs knowledge gaps and prioritization of limited resources. To date, mouse, hamster, ferret, guinea pig, and non-human primates have been investigated. Several species are permissive for SARS-CoV-2 replication, often exhibiting mild disease with resolution, reflecting most human COVID-19 cases. More severe disease develops in a few models, some associated with advanced age, a risk factor for human disease. This review provides a snapshot that recommends the suitability of models for testing vaccines and therapeutics, which may evolve as our understanding of COVID-19 disease biology improves. COVID-19 is a complex disease, and individual models recapitulate certain aspects of disease; therefore, the coordination and assessment of animal models is imperative.
KW - COVID-19
KW - SARS-CoV-2
KW - animal models
KW - hamsters
KW - macaques
KW - mice
KW - therapeutics
KW - vaccines
UR - http://www.scopus.com/inward/record.url?scp=85095431671&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85095431671&partnerID=8YFLogxK
U2 - 10.1016/j.chom.2020.09.016
DO - 10.1016/j.chom.2020.09.016
M3 - Review article
C2 - 33152279
AN - SCOPUS:85095431671
SN - 1931-3128
VL - 28
SP - 646
EP - 659
JO - Cell Host and Microbe
JF - Cell Host and Microbe
IS - 5
ER -